Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 7
Submit an article Journal homepage
547
Views
31
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials

Michael J. BurkeMedical College of Wisconsin and Children’s Hospital of Wisconsin, Milwaukee, WI, USA; Correspondence[email protected]
,
Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL, USA;
,
Kelly MaloneySchool of Medicine and Children’s Hospital of Colorado, University of Colorado, Aurora, CO, USA;
,
Anne AngiolilloChildren’s National Medical Center, Washington, DC, USA;
,
Reuven SchoreChildren’s National Medical Center, Washington, DC, USA;
,
Kimberly DunsmoreUniversity of Virginia Children’s Hospital, Charlottesville, VA, USA;
,
Eric LarsenMaine Children’s Cancer Program, Scarborough, ME, USA;
,
Len A. Mattano Jr.HARP Pharma Consulting, Mystic, CT, USA;
,
Wanda SalzerUS Army Medical Research and Materiel Command, Fort Detrick, MD, USA;
,
Stuart S. WinterHealth Sciences Center, University of New Mexico, Albuquerque, NM, USA;
,
William CarrollLaura and Issac Perlmutter Cancer Center at NYU, New York, NY, USA;
,
Naomi J. WinickSouthwestern Simmons Cancer Center, University of Texas, Dallas, TX, USA;
,
Mignon L. LohBenioff Children’s Hospital, University of California San Francisco, San Francisco, CA, USA;
,
Elizabeth RaetzDepartment of Pediatrics, University of Utah, Salt Lake City, UT, USA;
,
Stephen P. HungerChildren’s Hospital of Philadelphia, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
&
Archie BleyerDepartment of Pediatrics, Oregon Health and Science University, Portland, OR, USA
 show all
Pages 1624-1633 | Received 21 Feb 2017, Accepted 23 Oct 2017, Published online: 08 Nov 2017

References

  • Linet MS, Ries LA, Smith MA, et al. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Nat Cancer Inst. 1999;91:1051–1058.
  • Hunger SP, Loh ML, Whitlock JA, et al. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957–963.
  • Kawedia JD, Rytting ME. Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014;14:Suppl:S14–S17.
  • Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525–1532.
  • Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48:931–936.
  • Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554–563.
  • Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26:2303–2309.
  • Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671.
  • Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer. 2012;59:436–439.
  • Petersen WC, Jr., Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31:311–317.
  • Mattano LA, Devidas M, Friedmann AM, et al. Outstanding outcome for children with standard risk-low (SR-Low) acute lymphoblastic leukemia (ALL) and no benefit to intensified peg-asparaginase (PEG-ASNase) therapy: results of children’s oncology group (COG) study AALL0331. Blood. 2014;124:793.
  • Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children’s oncology group study AALL0232. J Clini Oncol. 2016;34:2380–2388.
  • Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: children’s oncology group study AALL0434. Pediatr Blood Cancer. 2015;62:1176–1183.
  • Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. J Clin Oncol. 2014;32:3874–3882.
  • Salzer W, Burke MJ, Larsen EC, et al. Incidence of allergic reactions to pegaspargase (PEG) administered intramuscularly versus intravenously (IM vs. IV) in children and young adults with high risk B-lymphoblastic leukemia (HR B-ALL): results of Children’s Oncology Group (COG) Studies AALL0232/AALL1131. Blood. 2015;126:1303.
  • Heitink-Polle KM, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
  • Jaing TH, Lin JL, Lin YP, et al. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31:955–956.
  • Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: a case series. J Oncol Pharm Practice. 2014;22:161–164.
  • Tong WH, Pieters R, de Groot-Kruseman HA, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica. 2014;99:1716–1721.
  • Steiner M, Attarbaschi A, Kastner U, et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer. 2007;49:640–642.
  • Jorck C, Kiess W, Weigel JF, et al. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2011;28:3–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.